Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype

International Journal of Neuropsychopharmacology

Volumn 11, Issue 5, 2008, Pages 727-728

  Breil, Fleur ^a   Verstuyft, Celine ^b   Orostegui, Lupe ^b   Buhl, Catherine ^a   Alvarez, Jean Claude ^c   Chouinard, Guy ^a   Becquemont, Laurent ^b   Corruble, Emmanuelle ^a,d  

^a Universite Paris Sud   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c Raymond Poincaré University Hospital   (France)

^d BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; CYTOCHROME P450 2D6; NORCLOMIPRAMINE; PAROXETINE; VENLAFAXINE;

ADULT; CASE REPORT; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENE DUPLICATION; GENOTYPE; HAMILTON SCALE; HUMAN; LETTER; MAJOR DEPRESSION; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL;

ANTIDEPRESSIVE AGENTS; CYTOCHROME P-450 CYP2D6; DEPRESSION; HUMANS; MALE; MIDDLE AGED; PHENOTYPE;

EID: 46449134175     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145708008742     Document Type: Letter

References (11)

1. Baumann P, Broly F, Kosel M, Eap CB (1998). Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping. Pharmacopsychiatry 31, 72.
2. Bertilsson L, Dahl ML, Sjoqvist F, Aberg-Wistedt A, Humble M, Johansson I, Lundqvist E, Ingelman-Sundberg M (1993). Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 341, 63.
3. Bodin L, Beaune PH, Loriot MA (2005). Determination of cytochrome P450 2D6 (CYP2D6) gene copy number by real-time quantitative PCR. Journal of Biomedicine and Biotechnology 3, 248-253.
4. de Leon J (2007). The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19. Journal of Clinical Psychopharmacology 27, 241-245.
5. Fava M, Rush AJ, Wisniewski SR, Nierenberg AA, Alpert JE, McGrath PJ, Thase ME, Warden D, Biggs M, Luther JF, et al. (2006). A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. American Journal of Psychiatry 163, 1161-1172.
6. Gex-Fabry M, Balant-Gorgia AE, Balant LP (1999). Clomipramine concentration as a predictor of delayed response: a naturalistic study. European Journal of Clinical Pharmacology 54, 895-902.
7. Kawanishi C, Lundgren S, Agren H, Bertilsson L (2004). Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. European Journal of Clinical Pharmacology 59, 803-807.
8. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmoller J (2004). Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Molecular Psychiatry 9, 442-473.
9. Malhotra AK, Murphy Jr. GM, Kennedy JL (2004). Pharmacogenetics of psychotropic drug response. American Journal of Psychiatry 161, 780-796.
10. Rau T, Wohlleben G, Wuttke H, Thuerauf N, Lunkenheimer J, Lanczik M, Eschenhagen T (2004). CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants - a pilot study. Clinical Pharmacology & Therapeutics 75, 386-393.
11. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry 163, 1905-1917.